Adverse reactions (ARs) during the infusion of cellular therapy products (CTPs) are common in patients undergoing hematopoietic stem cell transplantation (HSCT). We retrospectively studied pediatric patients undergoing autologous and allogeneic HSCT to determine the incidence and grade of ARs during stem cell infusion and their predictors. We analyzed data from 213 patients (120 allogeneic and 93 autologous) who received at least 1 CTP, totaling 361 infusion episodes. Serious ARs, defined as grade 2 and 3, occurred in 25 and 11% of infusions, respectively. No grade 4 or 5 ARs were noted. Independent risk factors for developing a serious AR included stem cell source (PBSC vs marrow (odds ratio (OR) 1.8, 95% confidence interval (CI): 0.4-9); cord vs marrow (OR 7.3, 95% CI: 1.3-40), overall P = 0.0001) but manipulated CTPs were protective (OR 0.4, 95% CI: 0.2-0.7, P = 0.004). Unlike previous adult studies, WBC and granulocyte content were not found to be risk factors in this pediatric population. These data suggest that children tolerate higher WBC content during infusion of CTPs and support the use of manipulated CTP, as indicated, to reduce the risk of adverse infusion reactions.
INTRODUCTION
The infusion of hematopoietic stem cells in blood and marrow transplantation is generally a safe procedure. Unlike receiving a simple blood transfusion, however, these infusions have the potential to cause a variety of adverse reactions (ARs). These range from common mild reactions including nausea, vomiting, flushing, fever, chills and cough [1] [2] [3] to rare life-threatening reactions affecting the cardiovascular, respiratory and neurological systems. [4] [5] [6] [7] Infusion-related ARs have been attributed to both cellular and non-cellular elements within the cellular therapy product (CTP). In addition to the desired CD34 + hematopoietic stem cells, CTPs contain a wide variety RBC, cytokines and WBC including mature granulocytes, lymphocytes and monocytes, all of which may contribute to infusion-related reactions. Furthermore, bone marrow stem cells, PBSCs, and cord blood stem cells (CBSC), each have unique attributes related to collection methods and storage, which may potentially cause reactions. For example, PBSCs typically contain a larger fraction of mature granulocytes and lymphocytes, whereas naive CBSC contain the least.
Current practices in autologous hematopoietic stem cell transplantation (HSCT) use DMSO as a protective agent to maintain cell viability in the cryopreservation process. The earliest reports of DMSO toxicity during stem cell infusion describe characteristic side effects such as nausea, vomiting, abdominal pain, chills and fever. 1, 2 Rare but serious side effects of cryopreserved products include severe respiratory depression, 7 neurotoxicity resulting in amnesia, loss of consciousness or seizure 5, 6 and fatal cardiac arrhythmia. 4 Efforts aimed at reducing the DMSO content of infused grafts either by washing or other means have resulted in a reduction of ARs among some studies, 8, 9 but not others. 10 No relationship between DMSO and ARs in cord blood transplants has been observed. 11 High WBC concentration, especially due to granulocytes or PMNs, has been associated with increased frequency and severity of ARs. [12] [13] [14] [15] Other risk factors include patient age and non-mononuclear cells, 13 total nucleated cell dose, 16, 17 RBC content 18 and infusion technique. 14 Overall, ARs occurs during infusion of stem cells in 23-76% of cryopreserved products, 1, 2, 14, 19 but almost all studies include only adults or a few pediatric patients but describe the population in aggregate. 13, 16, 17, 19 Our objective was to determine the incidence and grade of ARs occurring during the infusion of CTPs in pediatric patients undergoing allogeneic and autologous HSCT. We also examined risk factors for the development of ARs. To date, this is the first and largest study in an exclusive pediatric sample to study infusion-related ARs among both autologous and allogeneic HSCT recipients.
SUBJECTS AND METHODS Subjects
All pediatric patients (age o 19) undergoing allogeneic and autologous HSCT at the Alberta Children's Hospital from 2004 to 2012 were included in this retrospective chart review. This study was approved by the Conjoint Health Research Ethics Board of the University of Calgary. 5% concurrent plasma or human serum albumin at a maximum WBC concentration of 3 × 10 8 cells/mL. CTPs were stored in the vapor phase of liquid nitrogen. All patients receiving cryopreserved products received pre-medication with antihistamines, steroids and antiemetic drugs. On the day of infusion, patients received pre-and post-hydration with D5W 0.2% NaCl+50 mmol/L sodium bicarbonate at 125 mL/m 2 /h, for at least 2 h before CTP infusion followed by 8 h after. Cells were thawed at the bedside in a water bath at 37°C until complete disappearance of ice crystals and were infused directly via a central venous catheter. In the exceptional cases of clumping or visible debris, cells were infused through a 170-260 μm filter. Cryopreserved products were infused as fast as possible, usually at a rate of 999 mL/h.
Allogeneic SCT
Both PBSCs and bone marrow stem cells were collected from healthy allogeneic donors. PBSCs were collected after mobilization with G-CSF, with a targeted collection dose of 8 × 10 6 CD34+ cells/kg, according to our local practice. Bone marrow harvests were performed to collect a total nucleated cell dose of 5 × 10 8 total nucleated cell/kg. Allogeneic CTPs were routinely given fresh without need for pre-medication in the recipient. Donor-recipient ABO incompatibility required pre-medication with acetaminophen, antihistamines and steroids as indicated based on RBC volume and/or antibody titer. Although anti-ABO titers were initially measured in patients with minor ABO incompatibility, this procedure was ultimately discontinued as it did not change our requirement for manipulation of the product. In the case of major ABO incompatibility, RBC depletion was performed and CTPs were divided to contain o1 mL/kg of RBC per aliquot. Red cell depletion was performed by a gravity sedimentation method, by the addition of starch reagent (6% Hespan) to the cellular therapy (marrow) product, followed by slow drainage for removal. Volume reduction was performed if there were concerns about fluid overload. Pre and post hydration with D5W 0.2%NaCl+50 mmol/L sodium bicarbonate at 125 mL/m 2 /h was given for at least 2 h before CTP infusion followed by 8 h after. Fresh marrow and PBSC were infused at 10-15 mL/kg/h, with a minimum of 30 min even for the smallest volume.
CBSC products were obtained from accredited cord blood banks and all efforts were made to select CBSCs that were RBC depleted at time of storage. Before 2008, CBSC products were thawed at beside and infused without further manipulation. However, from 2008 to 2012, we adopted a washing (for RBC-replete products) or dilution step (for RBC depleted/buffy coat products) based on protocols published by Rubenstein et al. 20 CBSCs were infused as per our guideline for cryopreserved products.
Data collected
Pre-transplant data included patient gender, age, diagnosis, indication for HSCT, year of HSCT, conditioning regimen including chemotherapy and TBI doses. Transplant-related data included type of HSCT (allogeneic vs autologous), stem cell source (bone marrow, peripheral blood and cord blood), and number of stem cell infusions. Year of transplant was dichotomized into two transplant periods (2004-2008 vs 2009-2012) arbitrarily to study the global effect of time period on the outcome.
Cellular therapy product data
For fresh and cryopreserved CTPs, we collected all manipulation data (washed, plasma reduced, RBC reduced, diluted), and data on total WBC, CD34 + , CD45 + , CD3 + , mono-nuclear cells, granulocyte content and DMSO volume (for cryopreserved products). Infusion details including volume, duration of individual CTP infusions and total time of procedure (defined as the duration from the start of the first CTP infusion to the end of the last CTP infusion) were also obtained.
Outcome data
Infusion-related ARs were collected from the Day of Infusion Report Form (when available) as well as the patient's medical record. Vital signs were recorded every 5 min during the infusion of cryopreserved CTPs and every 15 min for an hour followed by every 30 min during the infusion of fresh CTPs. Continuous oxygen saturation monitoring was required during the infusion of all CTPs but continued for a minimum of 1 h after infusion was completed for cryopreserved CTPs. Data on 19 discrete ARs were collected: cough, nausea, vomiting, chest pain, tachycardia, bradycardia, flushing, pain (any site including abdominal, back or flank), headache, wheezing/ bronchospasm, loss of consciousness, visual disturbance, allergic reaction (skin rash/hives), decreased oxygen saturation, fever, diarrhea, chills, hypertension and hypotension. ARs were collected from day 0 during two distinct time periods: (1) from the start to end of the CTP infusion ('infusion period') and (2) during the 24 h following the end of the CTP infusion ('post-infusion period'). Severity of ARs was graded as per the Common Terminology Criteria for Adverse Events v4.0 (National Cancer Institute). In order to reduce false positives, we reviewed all patient records for ARs, which were already present before the day of CTP infusion (day − 1) and omitted those that pre-existed. As there were no grade 4 or 5 AR's, we defined serious ARs (SARs) as either a grade 2 or 3 AR. When more than one AR was reported per CTP infusion, the highest grade AR was recorded.
Data handling and analysis
Because of processing and patient requirements, some patients received multiple components (for example, multiple bags) of stem cells within a given HSCT. In addition, some patients were treated with multiple distinct transplants, each with repeated conditioning (tandem autologous HSCT or a second allogeneic HSCT). Each of these distinct transplants could involve multiple CTP components. For the purpose of this study, each CTP infusion was considered and analyzed as a separate event.
Descriptive statistics were used, where applicable. Categorical variables were compared using χ 2 tests. Continuous variables were compared using t-tests (parametric data) and Wilcoxon tests (non-parametric data). Risk factors for infusion reactions were analyzed using univariate regression. Factors that were significant on univariate analysis at P o0.1 were entered into a multivariate logistic regression model, using an automated backward selection approach. All statistical tests were two-sided with significance defined as Po0.05. Statistical analyses were performed in SAS, version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS

Study population
Our study included 213 transplant patients (120 allogeneic and 93 autologous). Compared with autologous HSCT, allogeneic HSCT occurred more often in the earlier time period (64% over [2004] [2005] [2006] [2007] [2008] , involved a variety of stem cell sources and were predominantly for leukemia (66%) ( Table 1 ). All autologous patients received cryopreserved PBSC, mostly for solid tumors (57%) or brain tumors (30%). Some patients received 41 HSCT and some HSCTs involved 41 CTP component infusion resulting in 148 allogeneic and 213 autologous CTP infusions; in total, there were 361 separate CTP infusions ( Table 1 ).
The majority of allogeneic patients received 1 CTP infusion in a single HSCT (n = 100). Six patients underwent a single HSCT but received 2 or more CTP infusions (range 2-4). The remaining 14 patients received 2 or more separate transplants and within each, had 1-2 CTP infusions, totaling 148 separate allogeneic CTP infusions (Table 2) .
Among autologous patients, 56 received a single HSCT, including 29 who received a single CTP infusion and 27 who received 2 or more CTP infusions. There were 37 patients treated with tandem or multiple autologous HSCT (range 2-4) with repeated conditioning, some of which involved multiple CTP infusions, totaling 213 separate autologous CTP infusions (Table 3) .
Infusion-related ARs
In order to minimize the false association of CTP infusions with ARs, we reviewed all charts for pre-existing signs and symptoms in the 24 h period preceding CTP infusion (day -1) and excluded 34 SARs in which this occurred.
Grade 1 ARs were the most common and occurred during the CTP infusion in 55% of cases and in the following 24 h after CTP infusion ended in 62% of cases (Table 4 ). The most common reactions were nausea and vomiting, which occurred most often in the 24 h period following the actual infusion (nausea, n = 153 (42%), vomiting, n = 100 (28%)).
Serious ARs, defined as grade 2 and 3, occurred during the CTP infusion in 10% and 4% of cases, respectively. In the 24 h period following the infusion, Grade 2 and 3 reactions occurred in 18% and 7% of cases, respectively. Over the entire period of interest, from the start of infusion to 24 h following the end of infusion, grade 2 and 3 ARs occurred in 25% and 11% of cases, respectively.
Grade 3 reactions occurring during the CTP infusion were rare and included 1 infusion with loss of consciousness, 9 infusions with hypoxia, and 6 infusions with hypertension. In the 24 h following CTP infusion there were 2 infusions with grade 3 pain, 1 infusion with grade 3 allergic reaction, 11 infusions with grade 3 hypoxia, 4 infusions with grade 3 fever, and 7 infusions with grade 3 hypertension. There were no grade 4 or 5 ARs. Collectively, SARs occurred in 111 (31%) CTP infusions either during the infusion or in the post-infusion period (Table 4) .
Among the 16 patients weighing o 10 kg, there was a slightly higher rate of SARs compared to others, though not significant (42% vs 30%, P = 0.5). These patients had an increased rate of grade 3 desaturation in the 24 h following CTP infusion compared to those weighing 10 kg and higher (3 cases (12.5%) vs 8 cases (2.4%), P = 0.03). ARs in this group were not related to volume, even when adjusted for weight (P = 0.3).
Univariate analysis
In univariate analysis, risk factors associated with a SAR included HSCT in the earlier transplant period (2004-2008) , allogeneic HSCT, the use of CBSC and a diagnosis of leukemia (Table 5 ). In the earlier transplant period, 37% of HSCTs were associated with a SAR vs 23% in the latter (P = 0.005). Among allogeneic HSCT, 46% were associated with SAR vs 20% in autologous HSCT (P o 0.0001). CBSC had a 50% chance of SAR, followed by 42% in marrow and 25% in PBSC (P = 0.0002). Infusions for an underlying diagnosis of leukemia had the highest association with 51% incidence of SAR, compared to all other diagnoses (P o 0.0001).
CTP component predictors There was no difference between the groups with non-serious ARs (NAR) and SAR with respect to CD34+ cells/kg, total WBC/kg, CD45+ cells/kg, CD3+ cells/kg, mononuclear cells kg and granulocytes/kg. To examine the effect of total WBC, we set two thresholds of WBC ⩾ 1 × 10 9 /kg and WBC ⩾ 2 × 10 9 /kg and found no difference between those with NARs and SARs. Pre-infusion manipulation of the CTP (plasma reduced, RBC reduced or buffy coat enrichment) was required in 61/230 infusions (27%) and was protective against SARs (P = 0.006) but washing alone was not. Larger volume of CTP (171 vs 139 mL, P = 0.03) was related to a longer duration of infusion (58 vs 37 min, P = 0.01) and were both associated with SAR. DMSO volume was similar between both the NAR and SAR group and did not reach significance (Table 6 ). Abbreviation: CTP = cellular therapy product. Individual components (bags) of CTPs were considered as a separate infusion.
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Treatment-related Factors
Patients who received a myeloablative dose of busulfan (12 mg/kg or higher) had a greater likelihood of SARs (P = 0.04). Interestingly, craniospinal irradiation (as part of therapy for brain tumors) was protective against SAR (P = 0.003), but TBI of 1200 cGy or more (as part of HSCT conditioning) was not (P = 0.01; Table 7 ). A history of allergic reaction to blood products had no association (P = 0.5). Pre-medications were given in 311 CTP infusions and were not significantly associated with protection against SARs (P = 0.33). Abbreviations: CTP = cellular therapy product; SAR = serious adverse reaction. Numbers do not match their sum, because some infusions were associated with both a grade 2 and 3 reaction; multiple ARs in a given CTP infusion were counted only once. Serious adverse reactions are defined as either grade 2 or 3 reaction; maximum grade was documented. Abbreviations: CTP = cellular therapy product; NAR = non-serious adverse reaction; SAR = serious adverse reaction. Abbreviations: CTP = cellular therapy product; MNC = mononuclear cells; NAR = non-serious adverse reaction; SAR = serious adverse reaction.
a Wilcoxon P-value used for non-parametric data.
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Multivariate analysis
In multivariate analysis, independent risk factors for the development of SARs were stem cell source with CBSC having the highest risk (CBSC vs bone marrow, odds ratio: 7.3, 95% confidence interval: 1.3-40; PBSC vs bone marrow, odds ratio 1.8, 95% confidence interval: 0.4-9, overall P = 0.0001). Manipulated CTPs were protective against SARs (odds ratio 0.4, 95% confidence interval: 0.2-0.7, P = 0.004). Gender, period of transplant, conditioning with busulfan, CSI, TBI, DMSO volume and total product volume had no effect in the multivariate model.
DISCUSSION
The infusion of CTPs in HSCT is generally a safe procedure with most patients experiencing only mild side effects. In the largest cohort of pediatric patients studied to date, we found that only 25 and 11% of CTP infusions were associated with grade 2 and 3 ARs, respectively. Almost all of these reactions were transient and easily treated. There were no life-threatening ARs or deaths (grade 4 and 5 reactions) that occurred during the infusion period or the 24 h post-infusion period. Our rate of infusion-related ARs is consistent with previous reports, 1, 2, 14, 19 although only a few studies actually graded severity. 12, 17, 21, 22 Commonly described ARs included nausea, vomiting, headache and cough. 3, 16, 18 Similarly, in our study, the most common ARs observed were nausea, vomiting, cough and fever.
We found two important predictors associated with ARs. The first predictor was CBSC, which had an odds ratio of 7.3 for developing an AR when compared with bone marrow stem cells. PBSC were similar to bone marrow stem cell with no significant difference. CBSC have traditionally been RBC replete and carried a small risk of reaction due to RBC lysis during the freeze/thaw process and the presence of stroma and debris in the cord blood product. 23 This may have been reflected in our data. Despite controlling for transplant period in our analysis, CBSC were still associated with the highest odds of developing a SAR.
A variety of methods are used for cord blood processing, which include washing, dilution or bedside thaw. 24 These methods have been shown to reduce RBC debris and DMSO volume/concentration and may contribute to lower rates of ARs. A no-wash dilution technique for CBSC resulted in infusion reactions that required additional therapy in 65% of patients; however, no serious life-threatening events occurred. 11 The reactions were hypertension, nausea, pain, fever, hypoxia and renal impairment and were not attributed to DMSO content.
The other important factor we found was that manipulated products were protective against developing an AR, which can be intuitively expected. Most CTP infusions in our study (n = 230, 64%) underwent one or more product manipulation procedures including RBC depletion, plasma depletion, washing or buffy-coat enrichment. As a result of these process measures, we observed a lower risk of AR during the infusion. An automated washing procedure was evaluated in 26 autologous patients receiving cryopreserved PBSC, and showed a significant reduction in adverse effects (26% in the non-washed products vs 2% in washed products) but no deleterious effect on CD34+ cells and time to neutrophil and platelet engraftment. 8 DMSO is essential for maintaining cell viability in the cryopreserved state but is toxic to cells when thawed and causes several ARs through histamine release resulting in cough, bronchospasm, hypotension, bradycardia and flushing. 25 Although many infusion-related ARs are attributable to DMSO, cellular therapy labs have established protocols to reduce this risk such as lowering the DMSO concentration to 5% in the final product, fractionated infusions and washing. 9 Many studies have shown a clear relationship between DMSO and incidence and/or severity of ARs. 2, 3, 22 Interestingly, in our pediatric population, we found no association with DMSO volume and ARs. The mean DMSO volume was 1.8 mL/kg in the NAR group and 1.5 mL/kg in the SAR group (NS), which is already well below our cell therapy lab guidelines.
Granulocyte content has also been identified to be associated with the presence and severity of ARs. In a study of 460 adults receiving autologous washed, DMSO-reduced infusions, 13.5% still had ARs. Patients with a Grade 1 or 2 AR (for example, nausea or vomiting) had three times more granulocytes (28 × 10 9 ) than those with no AR (8 × 10 9 ). However, those with a Grade 3/4 AR (for example, seizure or cardiac arrhythmia), had seven times more granulocytes (58 × 10 9 ) than those with no AR. 12 Another study confirmed this dose-dependent association reporting that a granulocyte concentration of 27.4 × 10 9 /L was associated with any side effect but granulocytes of 47.2 × 10 9 /L was associated with major side effects. 15 Our study found no relationship between granulocyte content and AR, however, the median granulocyte concentration was low in our study among both groups (median granulocyte 24 × 10 9 /L among NAR vs 25 × 10 9 /L among SAR, P = 0.9). Other reports have similarly identified granulocytes, 15, 19 non-mononuclear cells, 13 WBC, 26 and total nucleated cell dose 17 as important risk factors for developing ARs. One major mechanism of ARs in stem cell infusions is believed to be due to cell lysis followed by release of histamine and other cellular debris and contents into the patient's circulation. Granulocytes are more susceptible to cell lysis during the thawing process and the data support a higher number of granulocytes being associated with more adverse events. Elevation in serum lactate dehydrogenase levels, a reflection of cell lysis, from day − 1 to +1, was higher in the group of patients who had an AR compared with the group that had none. 13 Post-thaw CD45+ cell viability, a reflection of granulocyte lysis, was lower in a group of patients that had ARs compared with those without. 12 Interestingly, we found no association between WBC/kg, CD45+ cells/kg, mononuclear cells/kg, granulocytes/kg and risk of ARs. Even when we analyzed infusions with WBC ⩾ 1 × 10 9 /kg and WBC ⩾ 2 × 10 9 /kg, we found no difference in the NAR vs SAR group, although the numbers were small. One possibility is that children, owing to their lack of co-morbidities and pre-existing vascular disease, are more tolerable of high WBC content in CTP infusions compared with adults. Despite our findings, one patient in our study developed acute loss of consciousness (Grade 3) and hypoxia (Grade 3) following infusion of autologous PBSCs containing a high WBC ⩾ 2 × 10 9 /kg. This patient achieved a full recovery in the following hours, but review of the CTP showed a high concentration of granulocytes, 47 × 10 9 /L, and 20% DMSO 45 mL/kg, both of which exceed our current thresholds, and are known to cause severe reactions. Subsequently, we have revised our processing guidelines to minimize the cryopreservation of aliquots containing 41 × 10 9 WBC/kg, and in cases where this was Abbreviations: NAR = non-serious adverse reaction; SAR = serious adverse reaction.
Adverse stem cell infusion reactions in children TH Truong et al not possible, we have reduced the rate of infusion to avoid further ARs. The use of busulfan and TBI of 1200 cGy or higher were individually found to be associated with SARs, but not on multivariate analysis. Busulfan and TBI are both administered during the conditioning regimen and may contribute to more neurological ARs owing to their proximity to the day 0 stem cell infusion. In our study, they were associated with Grade 2/3 neurological ARs such as headache and vomiting, but also with hypoxia, fever and hypertension. There were no Grade 2/3 visual disturbance or LOC events in this group. The protective effect of craniospinal irradiation is an interesting finding that needs further study to see if it is reproducible. All of the patients who received craniospinal radiation were brain tumor patients who received CSI several days/weeks prior to stem cell infusion. Our hypothesis was that previous radiation exposure to the central axis may lead to more neurotoxicity but this was not seen. However, these patients typically received a lighter, usually non-myeloablative, conditioning regimen for their autologous transplants compared to the rest of the study patients.
Studies in the pediatric population examining infusion-related ARs are scant. One large pediatric report studied 54 children receiving cryopreserved PBSC autografts, and showed an AR rate of up to 74% with most children developing hemoglobinura (74%), headache (70%), nausea (69%) and vomiting (46%), 27 but these ARs were not graded and allogeneic grafts were not included. Another pediatric case report in a 16-year old boy described acute onset hyperosmolality with symptoms of severe headache, confusion and abdominal pain following infusion with cryopreserved autologous PBSC. He had a sudden rise in serum osmolality and hypernatremia, attributed to DMSO, but WBC/granulocyte content was not assessed. 28 Limitations to our study include the retrospective nature of the data collection, which is reliant on accurate reporting in the medical record. We did not collect data on pre-existing co-morbidities which may have impacted the outcome, however, the study was a consecutive sample of transplant patients over 9 years with no exclusion criteria. For the purpose of our study, we counted each CTP infusion as a separate event, which introduces bias as a few patients received multiple CTP infusions during the same transplant and their outcomes were included with those who just received one CTP infusion. We included all such patients on the basis that each CTP infusion may be unique in its cellular content and predisposition to AR.
In summary, stem cell infusion in pediatrics is a safe procedure in part reflecting the established supportive care measures in place to minimize ARs. Contrary to the adult literature, we found no association between DMSO or WBC/granulocyte concentration and the development of an SAR. Future prospective studies in children are needed to validate our findings and determine if other risk factors are associated with ARs, in order to inform guidelines and design appropriate interventions.
